Validation & Pathology Core

验证

• 批准号: 8555335
• 负责人: KENNETH K WANG
• 金额: $ 14.1万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-21 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8555335
• 关键词: Adenocarcinoma; Affinity; Barrett Esophagus; Binding; Biopsy; Clinical; Clinical Investigator; Clinical Research; Databases; Development; Dysplasia; Esophageal; Evaluation; Excision; Fluorescence; Gastroenterology; Genes; Genomics; Histopathology; Human Resources; Image; Label; Methods; Molecular Biology; Pathologist; Pathology; Peptides; Phase; Pilot Projects; Procedures; Recruitment Activity; Research; Research Project Grants; Research Support; Resolution; Role; Screening for cancer; Services; Specimen; Specimen Handling; Tissues; Ultrasonography; Validation; design; experience; fluorescence imaging; gastrointestinal; human subject; millimeter; novel; overexpression; validation studies

The Validation & Pathology Core consists of personnel with expertise in clinical gastroenterology, advanced procedures (endoscopic mucosal resection, endoscopic ultrasound), specimen processing, molecular biology, and pathology. Core personnel have many years experience in validation methods. The specific role of this BETRNet Specialized Research Rescource (Core) is to support the Research Center in the design and analysis of validation studies for the binding activity of fluorescent-labeled peptides to high-grade dysplasia and early adenocarcinoma for imaging in Barrett's esophagus. This Core will also support the three Primary Research Projects, developmental (Pilot) projects, cross-BETRNet projects, and other cross-BETRNet activities by providing methods and services for pathological evaluation of tissue specimens, including EMR and biopsy. The Validation & Pathology Core is organized into two parts: 1) the validation group which consists of clinical investigators and support staff that will recruit human subjects, collect specimens of Barrett's esophagus, administer selected fluorescent-labeled peptides, collect fluorescence images, and register fluorescence intensities with histopathology. These studies will be performed to validate affinity binding of the panel of peptides selected against amplified and overexpressed genes identified on the genomic database. Validation is critical to selection of an optimized set of peptides to be validated in the Phase 1 clinical studies with the proposed novel targeted imaging strategy; and 2) the pathology group which consists of gastrointestinal pathologists who will provide rigorous histopathology evaluation of the esophageal specimens that will be registered with the fluorescence images to sub-millimeter resolution.

验证和病理学核心由具有临床胃肠病学专业知识的人员组成， 手术（内镜粘膜切除术，内镜超声），标本处理，分子生物学， 和病理核心人员在验证方法方面具有多年经验。这其中的具体作用 BETRNet专业研究资源（核心）是支持研究中心的设计和 荧光标记肽与高度发育不良结合活性的验证研究分析， Barrett食管的早期腺癌。该核心还将支持三个主要 研究项目、发展（试点）项目、跨BETRNet项目和其他跨BETRNet项目 通过提供组织标本病理学评价的方法和服务，包括EMR， 和活检 验证和病理学核心分为两个部分：1）验证组，由临床 研究人员和支持人员将招募人类受试者，收集巴雷特食管标本， 施用选定的荧光标记肽，收集荧光图像，并记录荧光 强度与组织病理学。将进行这些研究以验证一组化合物的亲和力结合。 针对在基因组数据库上鉴定的扩增和过表达的基因选择肽。验证 这对于选择一组优化的肽在1期临床研究中进行验证至关重要， 提出了新的靶向成像策略; 2）病理组，包括胃肠道 病理学家将对食管标本进行严格的组织病理学评价， 与荧光图像配准到亚毫米分辨率。